RCKT Oct 2024 35.000 call
| Previous Close | 0.9000 |
| Open | 0.7800 |
| Bid | 0.0000 |
| Ask | 1.4000 |
| Strike | 35.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.7800 - 0.9000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 86 |
ZacksFDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Business WireRocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
CRANBURY, N.J., June 28, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I). The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (C
ZacksWhy Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
